AUG 20, 2017 7:53 PM PDT

Preventing Lethal Shock During Hemorrhagic Fevers

WRITTEN BY: Kara Marker

The body can go into “shock” for several different reasons, but it’s never a good sign. Whatever the source of shock, the condition is lethal if left untreated (and sometimes leads to death even with treatment). From the University of Basel, researchers are looking at a common cause of shock, hemorrhagic fevers from viral infections, to find new, more effective treatments.

A transmission electron micrograph (TEM) of a number of Lassa virus virions adjacent to some cell debris. Source: CDC's Public Health Image Library

Hemorrhagic fever describes what happens to the body when multiple body organs are damaged as the body’s vascular system is breaking down. When hemorrhagic fevers lead to shock, the body’s blood pressure is so low that there is not enough oxygen in the body to prevent organ failure. Someone in shock might feel cold, anxious, and confused, or look pale with dilated pupils. Treatment options often depend on what the source of shock is (it can be from an allergic reaction, infections in the blood, a heart deficiency, or even an emotional disturbance). Oxygen, IV fluids, blood transfusion, or blood vessel-constricting drugs to direct blood flow to the heart and brain are a few options.

Lassa virus is transmitted to humans by rodents, causing a hemorrhagic fever reminiscent of the Ebola virus. This type of infection is particularly common in West Africa, and at the very last stage of the disease, people go into shock, usually leading to death. In a new study published in the journal Cell Host & Microbe, researchers use Lassa virus as a way to study what happens in the body to trigger hemorrhagic fever, with the hope of using that information to someday develop new therapies.

Interestingly, researchers identified T cells at the root of circulatory failure. T cells are a key part of the adaptive immune system, the branch that designs a specific attack against pathogenic invaders, so implicating T cells in contributing to shock was surprising.

They found that T cells “convince” so-called “scavenger” cells to mass-produce nitric oxide (NO) by releasing a substance called interferon gamma. However, NO is an antibacterial chemical; it has no power over viral infections. Instead, NO triggers blood vessel dilation, the first step toward what will eventually be circulatory failure. However, researchers already see the benefits of blocking the production of interferon gamma to prevent circulatory failure.

With a key trigger of shock identified, researchers are already moving forward on applying this knowledge in the clinic to prevent shock-related death.

Sources: LiveScience, CDC, University of Basel

About the Author
  • I am a scientific journalist and enthusiast, especially in the realm of biomedicine. I am passionate about conveying the truth in scientific phenomena and subsequently improving health and public awareness. Sometimes scientific research needs a translator to effectively communicate the scientific jargon present in significant findings. I plan to be that translating communicator, and I hope to decrease the spread of misrepresented scientific phenomena! Check out my science blog: ScienceKara.com.
You May Also Like
SEP 06, 2020
Microbiology
Small Changes in Vaccine Molecules Could Make Them More Effective
SEP 06, 2020
Small Changes in Vaccine Molecules Could Make Them More Effective
Effective vaccines have to trigger an immune response, which is intended to create an immune 'memory' of a specific infe ...
SEP 24, 2020
Immunology
Remember That Coronavirus You Once Met? Your T Cells Do.
SEP 24, 2020
Remember That Coronavirus You Once Met? Your T Cells Do.
The SARS-CoV-2 virus was first identified in December 2019 in Wuhan, Hubei, China and quickly escalated to a pandemic st ...
SEP 20, 2020
Drug Discovery & Development
New Drug Combo Prolongs Survival with Advanced Kidney Cancer
SEP 20, 2020
New Drug Combo Prolongs Survival with Advanced Kidney Cancer
Biopharmaceutical company Bristol-Myers Squibb has found that a new drug combination can reduce death rates among those ...
OCT 06, 2020
Drug Discovery & Development
New Immunotherapy Drug Effective Against Lung Cancer
OCT 06, 2020
New Immunotherapy Drug Effective Against Lung Cancer
A new study has confirmed that Tecentriq, an immunotherapy drug, improves survival rates among those with newly diagnose ...
OCT 27, 2020
Immunology
The Genetics of Skin Inflammation, Seen With Unprecedented Clarity
OCT 27, 2020
The Genetics of Skin Inflammation, Seen With Unprecedented Clarity
A recent study published in Immunity details MIT scientists’ exploration of the underlying mechanisms of inflammat ...
NOV 12, 2020
Immunology
The Enzyme That Keeps Viruses In Stealth Mode
NOV 12, 2020
The Enzyme That Keeps Viruses In Stealth Mode
Some viral infections just don’t go away. The hepatitis C virus, for instance, can result in life-long chronic inf ...
Loading Comments...